← Leaderboards
Guido Marcucci
Beckman Research Institute/City Of Hope
$19,718,636
Attributed
$35,802,894
Total exposure
21
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,802,894 · 21
By mechanism
R01$20,151,465 · 8
U10$6,569,979 · 2
U01$4,798,756 · 2
R21$2,870,523 · 5
K08$662,180 · 1
P50$562,118 · 1
Top collaborators
- Ya-Huei Kuo16 shared
- Bin Zhang11 shared
- Ramiro Garzon10 shared
- Russell Christian Rockne7 shared
- Clara D Bloomfield5 shared
- Carlo M Croce5 shared
- Monica L Guzman5 shared
- Natarajan Muthusamy5 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Russell Christian Rockne$4,281,270
- Bin Zhang$2,891,856
- Le Xuan Truong Nguyen$831,127
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaCellsBone MarrowMolecularProteinsMicrornasDesignTherapeutic TargetClinical TrialsDoseChemotherapyPharmacodynamicsBaseMalignant NeoplasmsGenesIn VivoAcute Myelocytic LeukemiaDown-RegulationDrug KineticsResistanceMessenger RnaScheduleBloodClinic
Grant awards (89)
Targeting MicroRNAs to Eradicate Leukemia Stem Cells$1,011,514
R01 · FY2025 · CA
State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapy$590,960
U01 · FY2025 · CA
Targeting Immune Escape in CML/MPN Transformation$571,615
R01 · FY2025 · CA
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$542,890
R01 · FY2025 · CA · contact PI
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$623,198
U01 · FY2024 · CA
State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapy$590,960
U01 · FY2024 · CA
Targeting Immune Escape in CML/MPN Transformation$571,615
R01 · FY2024 · CA
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$515,745
R01 · FY2024 · CA · contact PI
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$485,048
R01 · FY2024 · CA · contact PI
Targeting MicroRNAs to Eradicate Leukemia Stem Cells$480,469
R01 · FY2024 · CA
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$700,616
U01 · FY2023 · CA
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$532,031
R01 · FY2023 · CA · contact PI
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$500,364
R01 · FY2023 · CA · contact PI
Targeting MicroRNAs to Eradicate Leukemia Stem Cells$495,641
R01 · FY2023 · CA
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$863,194
U01 · FY2022 · CA
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$542,890
R01 · FY2022 · CA · contact PI
Targeting MicroRNAs to Eradicate Leukemia Stem Cells$505,757
R01 · FY2022 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$500,361
R01 · FY2022 · CA · contact PI
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$714,914
U01 · FY2021 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$510,576
R01 · FY2021 · CA · contact PI
Targeting microRNAs to eradicate leukemia stem cells$497,136
R01 · FY2021 · CA
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$714,914
U01 · FY2020 · CA
Biologic and Therapeutic Significance of miR-155 in AML$528,129
R01 · FY2020 · CA · contact PI
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$510,576
R01 · FY2020 · CA · contact PI
Targeting microRNAs to eradicate leukemia stem cells$481,146
R01 · FY2020 · CA
Biologic and Therapeutic Significance of miR-155 in AML$515,834
R01 · FY2019 · CA · contact PI
Targeting microRNAs to eradicate leukemia stem cells$451,666
R01 · FY2019 · CA
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$684,551
U10 · FY2018 · CA
Biologic and Therapeutic Significance of miR-155 in AML$549,553
R01 · FY2018 · CA · contact PI
Targeting microRNAs to eradicate leukemia stem cells$450,769
R01 · FY2018 · CA
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$643,941
U10 · FY2017 · CA
Biologic and Therapeutic Significance of miR-155 in AML$554,107
R01 · FY2017 · CA · contact PI
Targeting microRNAs to eradicate leukemia stem cells$434,503
R01 · FY2017 · CA
Pharmacological modulation of epigenetic changes in AML$342,107
R01 · FY2017 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$687,345
U10 · FY2016 · CA
Biologic and Therapeutic Significance of miR-155 in AML$574,050
R01 · FY2016 · CA · contact PI
Pharmacological modulation of epigenetic changes in AML$342,107
R01 · FY2016 · CA · contact PI
Targeting the aberrant kinome-epigenome in AML$308,958
R01 · FY2016 · CA
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$691,472
U10 · FY2015 · CA
Pharmacological modulation of epigenetic changes in AML$359,607
R01 · FY2015 · CA · contact PI
Validation of microRNAs as therapeutic targets in hematological malignancies$316,438
R01 · FY2015 · CA
Targeting the aberrant kinome-epigenome in AML$307,671
R01 · FY2015 · CA
Leukemia Tissue Bank$44,226
P30 · FY2015 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$700,000
U10 · FY2014 · CA
Validation of microRNAs as therapeutic targets in hematological malignancies$306,945
R01 · FY2014 · CA
Pharmacological modulation of epigenetic changes in AML$300,948
R01 · FY2014 · CA · contact PI
Targeting the aberrant kinome-epigenome in AML$300,231
R01 · FY2014 · CA
Leukemia Tissue Bank$45,042
P30 · FY2014 · CA · contact PI
Cancer and Leukemia Group B - Leukemia Correlative Sciences$742,430
U10 · FY2013 · CA · contact PI
Pharmacological modulation of epigenetic changes in AML$322,878
R01 · FY2013 · CA · contact PI
Validation of microRNAs as therapeutic targets in hematological malignancies$297,452
R01 · FY2013 · CA · contact PI
Targeting the aberrant kinome-epigenome in AML$291,226
R01 · FY2013 · CA
SPORE Leukemia Tissue Bank$107,207
P50 · FY2013 · CA · contact PI
Leukemia Tissue Bank$43,416
P30 · FY2013 · CA · contact PI
Cancer and Leukemia Group B - Leukemia Correlative Sciences$806,740
U10 · FY2012 · CA · contact PI
Validation of microRNAs as therapeutic targets in hematological malignancies$316,438
R01 · FY2012 · CA · contact PI
Targeting the aberrant kinome-epigenome in AML$310,414
R01 · FY2012 · CA
SPORE Leukemia Tissue Bank$115,036
P50 · FY2012 · CA · contact PI
Leukemia Tissue Bank$46,435
P30 · FY2012 · CA · contact PI
Cancer and Leukemia Group B - Leukemia Correlative Sciences$783,858
U10 · FY2011 · CA · contact PI
Validation of microRNAs as therapeutic targets in hematological malignancies$316,438
R01 · FY2011 · CA · contact PI
Phamacological modulation of epigenetic changes in AML$291,000
R01 · FY2011 · CA · contact PI
SPORE Leukemia Tissue Bank$109,703
P50 · FY2011 · CA · contact PI
Cancer and Leukemia Group B - Leukemia Correlative Sciences$829,642
U10 · FY2010 · CA · contact PI
GTI-2040: An anti-sense strategy to reduce ribonucleotide reductase in AML$335,500
R21 · FY2010 · CA · contact PI
Phamacological modulation of epigenetic changes in AML$300,000
R01 · FY2010 · CA · contact PI
SPORE Leukemia Tissue Bank$115,500
P50 · FY2010 · CA · contact PI
GTI-2040: An anti-sense strategy to reduce ribonucleotide reductase in AML$335,500
R21 · FY2009 · CA · contact PI
Phamacological modulation of epigenetic changes in AML$300,000
R01 · FY2009 · CA · contact PI
Molecular characterization of normal cytogenetics AML in older patients$168,750
R21 · FY2009 · CA · contact PI
SPORE Leukemia Tissue Bank$114,672
P50 · FY2009 · CA · contact PI
Phamacological modulation of epigenetic changes in AML$300,000
R01 · FY2008 · CA · contact PI
Molecular characterization of normal cytogenetics AML in older patients$202,500
R21 · FY2008 · CA · contact PI
PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AML$299,274
R01 · FY2006 · CA · contact PI
Pharmacologic modulation of chromatin remodeling in leu*$259,492
R21 · FY2006 · CA · contact PI
LARG, A Novel Leukemia Associated Guanine Exhange Factor$55,215
K08 · FY2006 · CA · contact PI
PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AML$303,674
R01 · FY2005 · CA
Pharmacologic modulation of chromatin remodeling in leu*$265,736
R21 · FY2005 · CA
LARG, A Novel Leukemia Associated Guanine Exhange Factor$132,516
K08 · FY2005 · CA
A PHASE I STUDY OF DECITABINE IN COMBINATION WITH VALPROIC ACID$8,754
M01 · FY2005 · RR
Ribonucleotide Reductase Antisense Strategy in AML$319,788
R21 · FY2004 · CA
PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANGES IN AML$303,674
R01 · FY2004 · CA
LARG, A Novel Leukemia Associated Guanine Exhange Factor$132,516
K08 · FY2004 · CA
BCI2 Antisense Against Chemoresistance in Elderly AML$331,875
R21 · FY2003 · CA
Ribonucleotide Reductase Antisense Strategy in AML$319,788
R21 · FY2003 · CA
LARG, A Novel Leukemia Associated Guanine Exhange Factor$132,516
K08 · FY2003 · CA
BCI2 Antisense Against Chemoresistance in Elderly AML$331,594
R21 · FY2002 · CA
LARG, A Novel Leukemia Associated Guanine Exhange Factor$77,301
K08 · FY2002 · CA
LARG, A Novel Leukemia Associated Guanine Exhange Factor$132,116
K08 · FY2001 · CA